Valbiotis Announces the Release of the Universal Registration Document
19 Mai 2022 - 5:40PM
Business Wire
Regulatory News:
Valbiotis (FR0013254851 – ALVAL, PEA / PME eligible)
(Paris:ALVAL), a Research and Development company committed to
scientific innovation for preventing and combating metabolic
diseases, announces that its Universal Registration Document was
filed to the French Financial Markets Regulator (AMF) May 19,
2022.
This document is available to the public free of charge under
the conditions laid down in the regulations in force, and can be
consulted and downloaded from both the Valbiotis website
(www.valbiotis.com/en/regulatory-information/) and the AMF website
(www.amf-france.org/).
The document presents the highlights and financial information
for the year ended December 31, 2021 in addition to key events
since January 1, 2022, including:
- the approval to launch the two
Phase II/III INSIGHT and INSIGHT 2 multicentric international
clinical studies, with TOTUM•854, for the reduction of blood
pressure (Press release, February 17, 2022)
- the strengthening of its
commitment to CSR by joining the United Nations Global Compact and
applying the ISO 26000 standard (Press release, March 22, 2022)
- the positive results of its
clinical study on the bioavailability and mode of action of
TOTUM•070, against hypercholesterolemia (Press release, March 29,
2022)
- the first visit of the first
patient in the TOTUM•63 mode of action clinical study conducted by
the Laval University Institute of Nutrition and Functional Foods
(INAF) in Quebec City, in partnership with Nestlé Health Science.
The study has been officially launched, following the necessary
authorizations from Health Canada and the CERUL1 (Press release,
April 28, 2022).
Valbiotis will publish its half-year financial results on Friday
September 30, 2022.
About Valbiotis Valbiotis is a Research & Development
company committed to scientific innovation for preventing and
combating metabolic and cardiovascular diseases in response to
unmet medical needs. Valbiotis has adopted an innovative approach,
aiming to revolutionize healthcare by developing a new class of
health nutrition products designed to reduce the risk of major
metabolic diseases, relying on a multi-target strategy enabled by
the use of plant-based terrestrial and marine resources. Its
products are intended to be licensed to players in the health
sector. Created at the beginning of 2014 in La Rochelle, the
Company has forged numerous partnerships with leading academic
centers. The Company has established three sites in France –
Périgny, La Rochelle (17) and Riom (63) – and a subsidiary in
Quebec City (Canada). Valbiotis is a member of the "BPI Excellence"
network and has been recognized as an "Innovative Company" by the
BPI label. Valbiotis has also been awarded "Young Innovative
Company" status and has received major financial support from the
European Union for its research programs via the European Regional
Development Fund (ERDF). Valbiotis is a PEA-SME eligible company.
For more information about Valbiotis, please visit:
www.valbiotis.com
Name: Valbiotis ISIN code: FR0013254851 Mnemonic code: ALVAL
EnterNext© PEA-PME 150
This press release contains forward-looking statements about
Valbiotis’ objectives. Valbiotis considers that these projections
are based on rational hypotheses and the information available to
Valbiotis at the present time. However, in no way does this
constitute a guarantee of future performance, and these projections
may be affected by changes in economic conditions and financial
markets, as well as certain risks and uncertainties, including
those described in the Valbiotis Universal Registration Document
filed to the French Financial Markets Regulator (AMF) on May 19
2022. This document is available on the Company’s website
(www.valbiotis.com). This press release and the information it
contains do not constitute an offer to sell or subscribe, or a
solicitation to purchase or subscribe to Valbiotis’ shares or
financial securities in any country.
1Health Sciences Sectoral Committee of the Laval University
Ethics Committee for Research with human subjects
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220519005553/en/
Corporate communication / Valbiotis
Carole ROCHER Communications and Public affairs Director +33 6
77 82 56 88
Marc DELAUNAY Communication Manager +33 5 46 28 62 58
media@valbiotis.com
Financial communication / Actifin Stéphane RUIZ Associate
Director +33 1 56 88 11 14 sruiz@actifin.fr
Valbiotis (EU:ALVAL)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Valbiotis (EU:ALVAL)
Historical Stock Chart
Von Apr 2023 bis Apr 2024